The global extracorporeal membrane oxygenation (ECMO) system market accounted for USD 227.7 million in 2014 and is expected to reach USD 287.6 million by 2020 at a CAGR of 4.0% from 2015 to 2020.
The purpose of this report is to cover the definition, description, and forecast of Global Extracorporeal Membrane Oxygenation (ECMO) System market. It involves deep dive analysis of market segmentation which comprises of submarkets, modality and application. The report also offers strategic analysis of key players in the market. In this report, the Extracorporeal Membrane Oxygenation (ECMO) System market is segmented on the basis of its modality and application. In terms of modality, the market is segmented into Veno Artrial (VA), Veno Venous (VV), Artrio Venous (ECOO2 R).
This market has been segmented by application, which includes Respiratory, Cardiac, and Extra-Corporeal Cardiopulmonary Resuscitation (ECPR). The respiratory segment was the largest application of the global Extracorporeal Membrane Oxygenation (ECMO) System market in 2014.
Globally, North America contributed to the largest Extracorporeal Membrane Oxygenation (ECMO) System market in 2014. The large share is attributed to rise in the increasing number of patients suffering from respiratory failure and cardiopulmonary disease, rising incidence in Chronic Obtrusive Pulmonary Diseases (COPD), increasing adoption rate of ECMO machine in hospitals, technological advancements in ECMO system, success rate of ECMO and government initiatives and growing awareness towards ECMO. All these factors would help improve the demand of ECMO machines, which are used on a small scale in hospitals currently.
Furthermore, increasing number of patients suffering from respiratory failure and cardiopulmonary disease are other growth factors. With the rising number of cases globally, there is a boost in the growth of extra corporeal membrane oxygenators market. Respiratory failure may affect the muscles, nerves, bones, or tissues that support breathing, or they may affect the lungs directly. Over 3 million Canadians of all ages have a serious respiratory disease such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, tuberculosis (TB), cystic fibrosis, and respiratory distress syndrome. More than 5 million patients are admitted annually to ICUs in the U.S. In 2010, cardiovascular, lung, and blood diseases accounted for 1,017,000 deaths and 41 percent of all deaths in the U.S. However, cost of high end equipment, presence of conventional techniques, risk of complications, renal failure associated with ECMO are some of the restraints for the Extracorporeal Membrane Oxygenation (ECMO) System market.
The main companies operating in this market are MAQUET Holding B.V. & CO. KG. (Germany), SORIN Group (Italy), MEDTRONIC (Republic of Ireland), NIPRO Medical Corporation (U.S.), Terumo Medical Corporation (Japan), MicroPort Scientific Corporation (China), Medos Medizintechnik AG (Germany).
